102 results about "High fat diet" patented technology

The invention belongs to the field of biotechnology and nutritional medicine, relates to a maternal obesity intervention preparation, and particularly relates to a preparation method of a plant embryo fermentation product and application of the plant embryo fermentation product in blocking of trans-generation delivery metabolic diseases. FWG is prepared through a probiotic fermentation technology, obesity, glucose and lipid metabolism disorder and oxidative stress induced by high-fat diet of a parent body can be remarkably improved, and cross-generation transmission of metabolic diseases is blocked by adjusting composition of intestinal flora of the parent body and offspring and a hypothalamic PI3K-Akt signal channel. The invention reveals that maternal FWG intervention passes through a mechanism that a PI3K-Akt pathway is dominated and multiple pathways are coordinated on the transcriptome level for the first time, the HFD-induced offspring hypothalamus metabolism programming abnormality is reversed, and a new central regulation target is provided for cross-generation metabolic disease prevention. The FWG is a wheat processing byproduct, is free of chemical additives, is suitable for long-term dietary supplement, is a natural and safe nutrition intervention scheme, and is suitable for the field of maternal and infant health.

The application discloses a polypeptide composition for treating obesity and related metabolic diseases and application thereof. The polypeptide composition comprises polypeptide 1 and polypeptide 2, wherein the amino acid sequence of the polypeptide 1 is shown as SEQ ID NO. 1, can be specifically combined with the CD105 receptor on the surface of MSCs and the AdipoR1 receptor of adipocytes; the amino acid sequence of the polypeptide 2 is shown as SEQ ID NO. 2, can target adipose tissue and regulate glycolipid metabolism. The polypeptide composition is combined with fat-derived mesenchymal stem cells (MSCs) and applied to a high-fat-diet obese mouse model, and the results show that the composition has a significant synergistic effect in reducing body fat, improving the morphology of adipose tissue, regulating serum metabolic factors and inflammatory factors, and has no obvious organ toxicity. The application provides a new effective strategy and a safe and reliable pharmaceutical composition for treating obesity and related metabolic diseases.

The invention discloses an application of an intestinal strain in preparation of a cholesterol-lowering product, and belongs to the technical field of microbial medicines. The intestinal bacterial strain is Oscillibacter ruminant, the viable bacteria concentration of the intestinal bacterial strain is controlled to be (4.8-5.2) * 10 < 9 > CFU / mL, the intestinal bacterial strain can be prepared into bacterial liquid, freeze-dried powder, capsules or tablets and other dosage forms, and pharmaceutically acceptable auxiliary materials such as lactose and microcrystalline cellulose can be added. According to the cholesterol-lowering product, the total cholesterol, triglyceride and low-density lipoprotein cholesterol level of an object can be remarkably reduced under the action of peste des petits ruminants, and meanwhile, the high-density lipoprotein cholesterol level is increased; in addition, abnormal blood glucose induced by high-fat diet can be improved, arterial lipid accumulation is reduced, and the plaque area proportion of atherosclerotic lesions is improved.

The invention relates to the technical field of biological medicines, and discloses application of INHBC as a target spot in prevention and / or treatment of metabolic diseases. Specifically, the invention relates to application of substances for promoting INHBC gene expression or improving protein activity in preparation of products for preventing and / or treating metabolic diseases, and the metabolic diseases comprise diseases caused by energy metabolism disorder, such as obesity, diabetes, fatty liver disease, hyperlipidemia and the like. According to the application disclosed by the invention, liver specific overexpression or INHBC knock-in can improve mouse liver fatty degeneration and abnormal glucose metabolism induced by high fat diet, and in addition, the heat production activity of mouse adipose tissues can be enhanced, so that obesity induced by high fat diet is inhibited; the compound has an important application value in preventing and / or treating metabolic diseases such as obesity, type 2 diabetes and fatty liver diseases.

Disclosed herein are a means to prevent and / or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

The invention relates to the technical field of biological medicines, in particular to application of tetramer-form pyruvate kinase type 2 (PKM2) in preparation of a medicine for treating obesity. Pyruvate kinase type 2 is a key enzyme in a glycolytic pathway and has two conformations of dimer and tetramer, and the tetramer-form enzyme has high activity. The invention discovers that the PKM2 tetramer stabilizer TEPP-46 can stabilize PKM2 in a high-activity tetramer state and improve obesity-related metabolic disorder induced by high fat diet. The invention discloses a new way for regulating and controlling energy metabolism by stabilizing the form of the PKM2 tetramer, and provides a new medicine application direction for treating obesity and related metabolic diseases.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

The invention relates to a construction method and application of a high-fat diet induced mouse model with abnormal reproductive endocrine metabolism. The method comprises the following steps that after being born, a mouse is fed with high-fat milk for 3 weeks and then fed with high-fat feed for 5 weeks, and the high-fat diet induced abnormal reproduction metabolism mouse model is obtained when the mouse is 8 weeks old. According to the scheme provided by the invention, the high-fat mouse can be at the optimal fertility age in the modeling period and is closer to the condition of a clinically right-age obese patient, the fertility women in the clinical fertility age period are accurately simulated, and the age interference caused by the long modeling period of a traditional model is overcome.

The present application provides a polypeptide composition with anti-obesity effect, which is composed of capsaicin and polypeptides, and the amino acid sequence of the polypeptides comprises any one or more of SEQ ID NO. 1 to SEQ ID NO. 8. The polypeptides of sequences 1-8 are mixed uniformly at a mass ratio of 1-20:1-4:1-2:1-4:1:1:1:1, and the capsaicin is mixed with the mixed polypeptides at a ratio of 2-12:100 (w / w). The polypeptide composition proposed in the present application, in combination with capsaicin, not only promotes the weight loss effect of capsaicin, but also significantly reduces the fat index of the test mice after use, and can significantly reduce the total cholesterol concentration in the liver and the liver triglyceride concentration under a high-fat diet.

The application belongs to the technical field of cell biology, and particularly relates to a solution rich in Sargassum fusiforme nano-vesicles and a preparation method and application thereof. The solution rich in Sargassum fusiforme nano-vesicles is prepared by a differential centrifugation combined with hollow fiber membrane concentration, and the obtained solution rich in Sargassum fusiforme nano-vesicles can play an anti-inflammatory role, inhibit high-fat diet induced fatty liver and osteoporosis, and can also be used for preparing a mask with soothing, moisturizing and anti-wrinkle effects.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

The invention discloses a method for establishing a cross-generation genetic model of rats attacking nutritional imbalance twice, and relates to the technical field of animal model establishment, and the key points of the technical scheme are as follows: starting from the angle of paternal line, selecting SD male rats of 3 weeks old, adaptively feeding for 1 week, then starving and feeding for 4 weeks, and finally feeding for 17 weeks with high fat, evaluating the phenotype of fatty liver, and establishing the cross-generation genetic model of rats attacking nutritional imbalance twice. And establishing a parent (F0) which attacks the nutritional imbalance twice. After the parent generation (F0) and the normal exposed parent generation (F0) are mated, the male offspring (F1) is given with common diet and high-fat diet respectively, then after the parent generation (F0) and the normal exposed female generation (F0) are mated, the male offspring (F2) is given with common diet and high-fat diet respectively. According to the method, the fatty liver phenotype of the male rat of the F0-F2 model can be determined, and the glucolipid metabolism pathway and function change of the parental generation and the offspring generation can be known through an isotopic tracing technology, metabonomics and transcriptomics.

A composition contains a combination of at least one fiber and at least one probiotic and is formulated for administration to a subject in a condition of challenged gut microbiome such that the combination of at least one fiber and at least one probiotic improves and / or maintains optimal cholesterol levels in a subject in a condition of challenged gut microbiome. Preferably the subject is experiencing a microbiome stressor, such as one or more of a dietary stressor, antibiotic, other medications, infections, intense exercise, stress, alcohol, travel and combinations thereof; more preferably at least a dietary stressor; most preferably at least a high fat diet, such as a Western high fat diet or a ketogenic diet. The method can achieve at least one result that is improving and / or maintaining optimal cholesterol levels in a subject in a condition of challenged gut microbiome.

The invention discloses a roxburgh rose lactic acid bacteria solid beverage and application thereof in preparation of foods, health-care products or medicines for reducing hyperlipidemia, preventing colitis and resisting oxidation, and belongs to the field of probiotic health-care foods. The rosa roxburghii tratt lactic acid bacteria solid beverage is prepared from plant lactobacillus R-15, rosa roxburghii tratt fine powder, mannan oligosaccharide, resistant dextrin, coix lacryma-jobi extract, hawthorn extract, silicon dioxide and the like. The rosa roxburghii tratt lactobacillus solid beverage can significantly reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in the liver and serum of a mouse, inhibit fatty degeneration of the liver, and inhibit colitis induced by high fat diet. The invention has important application value in prevention and treatment of hyperlipidemia and colitis.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

The invention discloses an application of isolithocholic acid in preparation of a medicine for preventing or treating colorectal cancer induced by high fat diet. The invention proves that the isolithocholic acid can be accurately replenished by intragastric administration of 100g / kg of isoLCA at one time, and meanwhile, the isolithocholic acid can obviously inhibit the occurrence of obesity-related colon tumors, reduce the proliferation index of tumor cells and repair the intestinal barrier structure. Isolithocholic acid is endogenous secondary bile acid, can be chemically synthesized or semi-synthesized, is high in safety and good in patient compliance through oral administration, is expected to reduce the occurrence rate of colorectal cancer of obese people, and has important significance in treatment of colorectal cancer.

The invention discloses an application of ganoderic acid A in preparation of a product for preventing and / or treating a non-alcoholic fatty liver disease. The ganoderic acid A can regulate bile acid reabsorption of C57BL / 6J mice induced by high fat diet and reduce absorption of triglyceride and cholesterol. The ganoderic acid A can also enhance expression of a key enzyme cholesterol 7alpha-hydroxylase gene for liver cholesterol decomposition, so that liver cholesterol is promoted to be converted into bile acid, and accumulation of liver cholesterol is relieved. The ganoderic acid A has remarkable prevention and improvement effects on the non-alcoholic fatty liver disease induced by high fat diet by regulating bile acid metabolism, inhibiting lipid absorption and relieving liver lipid accumulation. Therefore, the ganoderic acid A can be used as a health-care product, a functional product or a medicine for preventing and treating the non-alcoholic fatty liver disease.

The invention discloses application of a Ttbk2 gene as a target spot in weight loss and lipid reduction, and belongs to the technical field of biological medicines. Research finds that overexpression of the Ttbk2 gene in a mouse obesity model induced by high fat diet can significantly improve obesity signs, specifically weight loss and fat content reduction. The invention finds that the Ttbk2 gene is an important therapeutic target for obesity and is also a key target for energy metabolism and lipid metabolism, and provides a theoretical basis and technical support for research and development of lipid-lowering drugs or weight-losing products.

The invention provides a recombinant human lactoferrin milk tablet with weight losing and blood sugar reducing functions and a preparation method thereof, and belongs to the technical field of dairy product processing. The recombinant human lactoferrin milk tablet disclosed by the invention is prepared from the following components in parts by mass: 95 to 105 parts of recombinant human lactoferrin, 3 to 4 parts of zinc gluconate, 1 to 1.5 parts of vitamin E, 0.03 to 0.04 part of folic acid and 1300 to 1400 parts of milk powder. Experiments prove that the recombinant human lactoferrin milk tablet prepared by the invention can slow down the weight gain of mice and relieve the impaired glucose metabolism capability caused by high fat diet, and meanwhile, the recombinant human lactoferrin can regulate the lipid degeneration of the liver to a certain extent, relieve the lipid deposition of the liver and inhibit fat cell hypertrophy. The recombinant human lactoferrin milk tablet has the weight-losing and blood-glucose-reducing effects for the first time, and has a wide application prospect in the field of weight losing and blood glucose reducing in the future.

The invention relates to an application of Chinese yam glycoprotein in preparation of a medicine for treating obesity, wherein the obesity is caused by high fat diet. The Chinese yam glycoprotein is derived from a natural plant Chinese yam, the biomacromolecule biological activity of the Chinese yam glycoprotein can be kept to the maximum extent through low-temperature grinding, separation and purification, and the product obtained through extraction and purification can be prepared into various dosage forms such as capsules, tablets, powder and oral liquid. Screening and verification are carried out through animal experiments, and it is proved that the Chinese yam glycoprotein has a remarkable fat reducing effect on obesity caused by high-fat diet, can improve the histological morphology of white adipose tissue, reduces the hypertrophy degree of adipose cells, meanwhile, improves abnormal glucose tolerance induced by the high-fat diet, and has an obvious fat reducing effect on obesity caused by the high-fat diet. And the expression of key factors related to adipogenesis and metabolic homeostasis in adipose tissues is regulated and controlled.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The invention discloses lignin-triiodothyronine self-assembled particles as well as a preparation method and application thereof. The lignin-triiodothyronine composite nano particles are prepared from lignin and triiodothyronine in a joint self-assembly mode. Experiments prove that single in-situ injection of the lignin-triiodothyronine composite nanoparticles can increase the expression of subcutaneous adipose tissues UCP-1 of normal diet fed mice and reduce adipose cells; single in-situ injection can increase the expression of subcutaneous adipose tissue UCP-1 of a mouse fed with short-term high-fat diet, reduce the weight of adipose tissue, increase the energy consumption of the mouse and improve the glucose tolerance of the mouse; multiple times of in-situ injection can improve obesity and fatty liver caused by long-term high-fat diet. The lignin-triiodothyronine composite nanoparticle provided by the invention has a good application prospect in treating, relieving or improving obesity or metabolic diseases related to the obesity.

The invention relates to the technical field of biological medicines, in particular to polypeptide for treating non-alcoholic fatty liver diseases. The invention provides a novel octapeptide P3-1 (SEQ ID NO: 1) derived from macadamia nuts. The novel octapeptide P3-1 (SEQ ID NO: 1) can remarkably improve liver lipid metabolism disorder, restore liver functions, relieve inflammatory response and increase abundance of probiotics in mice with non-alcoholic fatty liver diseases induced by high fat diet. The polypeptide is small in molecular weight, safe in source and easy to absorb, has good medicinal and health-care food development potential, and provides a safe and effective new way for targeted intervention of the non-alcoholic fatty liver disease.

Light is fundamental for biological life, with most mammals possessing light-sensing photoreceptors in various organs. Opsin3 is highly expressed in adipose tissue which has extensive communication with other organs, particularly with the brain through the sympathetic nervous system (SNS). Our study reveals a new light-triggered crosstalk between adipose tissue and the hypothalamus. Direct blue-light exposure to subcutaneous white fat improves high-fat diet-induced metabolic abnormalities in an Opsin3-dependent manner. Metabolomic analysis shows that blue light increases circulating levels of histidine, which activates histaminergic neurons in the hypothalamus and stimulates brown adipose tissue (BAT) via SNS. Blocking central actions of histidine and denervating peripheral BAT blunts the effects of blue light. Human white adipocytes respond to direct blue light stimulation in a cell-autonomous manner, highlighting the translational relevance of this pathway. Together, these data demonstrate a light-responsive metabolic circuit involving adipose-hypothalamus communication, offering a potential strategy to alleviate obesity-induced metabolic abnormalities.

The invention discloses an application of bifidobacterium animalis subsp. Lactis SS9 in preparation of a product for preventing and treating stress obesity. The bifidobacterium animalis subsp. Lactis SS9 obtained by screening can remarkably relieve obesity induced by combination of chronic pressure and high-fat diet, and the obesity is represented by slowing down weight increase, reducing appetite, improving blood fat, up-regulating GLP-1 and insulin secretion and effectively relieving anxiety-like and depression-like behaviors. Researches find that the strain can regulate the hypothalamic-pituitary-adrenal axis activation level, improve secretion imbalance of hormones such as CRH, ACTH and CORT, restore expression of appetite regulation factors such as NPY / AgRP / POMC of hypothalamic and relieve emotional eating behaviors. In addition, the strain can also reduce the systemic inflammation level, recover the diversity of intestinal flora and improve the proportion of beneficial bacteria. The invention provides the probiotics with multiple effects of regulating emotion, controlling body weight and improving metabolic disorder, and a new strategy is provided for preventing and treating stress-related obesity.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

Use of ganoderic acid A in the preparation of a product for preventing and / or treating non-alcoholic fatty liver disease. Ganoderic acid A can regulate bile acid reabsorption in C57BL / 6J mice induced by a high-fat diet, and reduce the absorption of triglycerides and cholesterol. Ganoderic acid A can also enhance the expression of the gene of cholesterol 7α-hydroxylase, a key enzyme for liver cholesterol decomposition, thereby promoting the conversion of liver cholesterol into bile acid, and alleviating the accumulation of liver cholesterol. Ganoderic acid A has a significant preventive and ameliorative effect on non-alcoholic fatty liver disease induced by a high-fat diet by means of regulating bile acid metabolism, inhibiting lipid absorption, and reducing liver lipid accumulation. Therefore, ganoderic acid A can be used as a health care product, a functional product, or a drug for preventing and treating non-alcoholic fatty liver disease.